Tyrosine Kinase Inhibitors: all 10,744 studies that test it

Page 104 of 108. Open to participants first (1,949), then studies with results posted, then the rest; newest registration first within each.

• Macugen for HistoplasmosisTerminatedNCT00272766Not applicable
• ZD6474 to Treat Advanced Brain Cancer in PatientsCompletedNCT00272350Phase 1
• SU11248 as Consolidation After Response to Taxanes in Metastatic Breast CancerCompletedNCT00270413Phase 2
• Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer PatientsCompletedNCT00268918Phase 1
• Comparison Study of WBRT and SRS Alone Versus With Temozolomide or Erlotinib in Patients With Brain Metastases of NSCLCStatus unknownNCT00268684Phase 3
• Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung CancerWithdrawnNCT00268255Phase 1/2
• Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00268229Phase 1
• Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract CancerCompletedNCT00266097Phase 1
• AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00265876Phase 1/2
• Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)CompletedNCT00265824Phase 3
• Trial of Iressa in Prostate Cancer PatientsCompletedNCT00265070Phase 2
• Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate TherapyCompletedNCT00264160Phase 2/3
• Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube CancerCompletedNCT00263822Phase 3
• PTK and Letrozole in Post-menopausal Women With Advanced Breast CancerTerminatedNCT00263198Phase 2
• Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The EsophagusCompletedNCT00259987Phase 2
• Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer PatientsCompletedNCT00259129Phase 1
• Iressa v BSC (Best Supportive Care) in First Line NSCLCCompletedNCT00259064Phase 2/3
• Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction CancerCompletedNCT00258323Phase 2
• Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By SurgeryTerminatedNCT00258297Phase 2
• Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00258271Phase 1
• To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer PatientsCompletedNCT00258050Phase 1
• Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple MyelomaCompletedNCT00256880Phase 2
• Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00255658Phase 1
• A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung CancerCompletedNCT00255489Phase 1
• Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following SurgeryCompletedNCT00254384Phase 1
• Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal TumorsCompletedNCT00254267Phase 2
• Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00253578Phase 2
• Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00253565Phase 1
• A Study of ZD1839 Effects on Cell Proliferation in Breast CancerWithdrawnNCT00252811Phase 2
• ZD6474 Phase IIa Dose Finding Multicentre StudyCompletedNCT00252746Phase 2
• GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerTerminatedNCT00251433Phase 1
• A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail GleevecCompletedNCT00250042Phase 2
• Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT00248482Phase 2
• Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis PatientsWithdrawnNCT00248053Phase 2
• The Efficacy of Coenzyme Q10 And Curcumin in Patients With Myelodysplastic SyndromesWithdrawnNCT00247026Phase 1/2
• Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCTCompletedNCT00246974Phase 2
• Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00245154Phase 2/3
• Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced CancerCompletedNCT00244972Phase 1
• Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive LeukemiaCompletedNCT00244829Phase 1/2
• Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic CancerCompletedNCT00243854Phase 1
• TKI258 in Subjects With Refractory or Relapsed Multiple MyelomaTerminatedNCT00243763Phase 1
• Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate CancerCompletedNCT00242918Phase 2
• Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple MyelomaTerminatedNCT00242827Phase 2
• Iressa vs Best Supportive Care - 2nd/3rd Line Survival StudyCompletedNCT00242801Phase 3
• IRESSA™ In Combo With Xeloda™ in Advanced Colorectal Cancer Patients After 1st-Line Chemo FailureCompletedNCT00242788Phase 1/2
• ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck CancerCompletedNCT00242762Phase 2
• IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck CarcinomaCompletedNCT00242749Phase 2
• Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or RadiotherapyCompletedNCT00241475Phase 2
• Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast CancerCompletedNCT00239343Phase 2
• Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck CancerCompletedNCT00239304Phase 1/2
• Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate CancerCompletedNCT00239291Phase 1/2
• Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma EsophagusTerminatedNCT00239200Phase 2
• A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma MultiformeCompletedNCT00238797Phase 2
• A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung CancerCompletedNCT00238628Phase 1/2
• Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00238394Phase 2
• Radiation Therapy Combined With Either Gefitinib or Temozolomide in Pats With NSCLC and Brain MetastasesCompletedNCT00238251Phase 2
• S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT00238212Phase 2
• Gefitinib in Combination With Chemoradiation in Resectable Gastric CancerTerminatedNCT00237900Phase 1/2
• Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)CompletedNCT00237172Phase 2
• Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)CompletedNCT00237120Phase 3
• Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe PsoriasisCompletedNCT00236119Phase 2
• Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLCTerminatedNCT00234468Phase 3
• Iressa in the Treatment of Brain Metastases From Non Small Cell Lung CancerTerminatedNCT00234442Phase 2
• A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal CarcinomaCompletedNCT00234429Phase 2/3
• A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast CancerCompletedNCT00234403Phase 2
• Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT00233636Phase 2
• Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal CancerWithdrawnNCT00233623Phase 2
• Phase II Gleevec Idiopathic Hypereosinophilic SyndromeTerminatedNCT00230334Phase 2
• Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa StudyCompletedNCT00229697Phase 2
• Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck CarcinomaCompletedNCT00228488Phase 2
• Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine TumorsWithdrawnNCT00227773Phase 2
• Erlotinib in Treating Patients With Progressive Glioblastoma MultiformeTerminatedNCT00227032Phase 1
• PTK787 in Patients With Advanced Metastatic Pancreatic AdenocarcinomaCompletedNCT00226005Phase 2
• Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF-00299804 In Patients With Advanced Solid TumorsCompletedNCT00225121Phase 1
• Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung CancerCompletedNCT00222144Phase 2
• Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous PatientsTerminatedNCT00219765Phase 1/2
• Safety and Efficacy of Imatinib in Chronic Myelogenous Patients Older Than 70 YearsCompletedNCT00219752Phase 2
• STI571 ProspectIve RandomIzed Trial: SPIRITCompletedNCT00219739Phase 3
• Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell TransplantationCompletedNCT00219726Phase 2
• Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00217698Phase 2
• Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
• Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube CancerCompletedNCT00217529Phase 1/2
• Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian CancerCompletedNCT00216112Phase 2
• PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast CancerTerminatedNCT00216047Phase 1/2
• Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric CarcinomasCompletedNCT00215995Phase 2
• Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)CompletedNCT00215670Phase 2/3
• Study of XL184 (Cabozantinib) in Adults With Advanced MalignanciesCompletedNCT00215605Phase 1
• Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)CompletedNCT00215202Phase 2
• A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839CompletedNCT00212108Phase 1/2
• Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric AdenocarcinomaTerminatedNCT00209079Phase 2
• MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00207103Phase 1
• Study of Cetuximab in Combination With Tarceva in Patients With Solid TumorsCompletedNCT00207077Phase 1
• BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal MalignanciesCompletedNCT00207051Phase 1
• MAD Refractory: Solid Tumor QD w/o BreakCompletedNCT00207012Phase 1
• Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer PatientsTerminatedNCT00206492Phase 2
• Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast CancerTerminatedNCT00206414Phase 2
• OSI-774 (Erlotinib, Tarceva) in Elderly PatientsCompletedNCT00200395Phase 2
• Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)Status unknownNCT00199186Phase 2
• Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00199160Phase 2
• Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IVCompletedNCT00198393Phase 2

← Tyrosine Kinase Inhibitors overview